Highlights of important announcements on February 7

Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd(603707) : furosemide injection was approved by FDA

Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd(603707) announced that the company’s subsidiary, Jianyou Hong Kong, recently received the approval letter of furosemide injection issued by the U.S. Food and Drug Administration (FDA). The indications of the drug are edema diseases, including congestive heart failure, liver cirrhosis, kidney diseases, etc. The newly approved products will be listed and sold in the United States, which is expected to have a positive impact on the company’s operating performance.

Suntar Environmental Technology Co.Ltd(688101) : Xuchang raised investment project will resume work on February 8

According to the announcement of Suntar Environmental Technology Co.Ltd(688101) , Suntar Environmental Technology Co.Ltd(688101) Xuchang raised investment project base will resume work in an orderly manner from February 8, 2022 on the basis of completing the relevant epidemic prevention and protection requirements. The company will spare no effort to reduce the losses caused by temporary shutdown and ensure the safe operation of the company.

Zhejiang Huayou Cobalt Co.Ltd(603799) approval of the application for public issuance of convertible bonds

According to the announcement of Zhejiang Huayou Cobalt Co.Ltd(603799) , the company recently received the reply issued by the China Securities Regulatory Commission, which approved the company to publicly issue convertible corporate bonds with a total face value of 7.6 billion yuan for a period of six years.

Jinko Power Technology Co.Ltd(601778) the proposed 300MW photovoltaic power generation project in Saudi Arabia

Jinko Power Technology Co.Ltd(601778) announced that the company plans to invest in the construction of 300MW photovoltaic power generation project in Saudi Arabia (hereinafter referred to as “Saudi project”). The actual construction scale of Saudi Arabia project is about 348.80mwp, and the total investment of the project is about 209 million US dollars (equivalent to about 1.325 billion yuan).

Shanghai Shine-Link International Logistics Co.Ltd(603648) shareholders plan to reduce their holdings of no more than 4.33% of the company’s shares

Shanghai Shine-Link International Logistics Co.Ltd(603648) announcement: Jiarong investment, a shareholder holding 4.33%, plans to reduce its holdings of no more than 15963133 shares of the company through centralized bidding trading and block trading within six months after three trading days from the date of this announcement, accounting for about 4.33% of the total share capital of the company.

Jiangsu Dingsheng New Material Joint-Stock Co.Ltd(603876) shareholders plan to reduce their holdings of no more than 2% of the company’s shares

Jiangsu Dingsheng New Material Joint-Stock Co.Ltd(603876) announcement: Jiangsu coastal, a shareholder holding 3.01%, plans to reduce its holdings by no more than 2% of the total share capital of the company through centralized bidding within 6 months after 15 trading days from the date of disclosure of the announcement.

Lucky Film Company Limited(600135) shareholders plan to reduce their holdings of no more than 2% of the company’s shares

Lucky Film Company Limited(600135) announcement: Pengshan Xincheng, a shareholder holding 7.90% of the shares, plans to reduce the shares of the company by means of centralized bidding within six months after 15 trading days from the date of the announcement, which shall not exceed 11065269 shares and 2% of the total share capital of the company.

Some shares held by Tibet Summit Resources Co.Ltd(600338) controlling shareholders will be auctioned by judicial disposal

Tibet Summit Resources Co.Ltd(600338) announced that the company learned from the Shanghai financial court and the online information platform of Shanghai Stock Exchange, and verified and confirmed with the controlling shareholder of the company Tacheng international that the Shanghai financial court will open the judicial disposal auction of stocks on the judicial assistance execution platform of bulk stocks of Shanghai Stock Exchange on March 4, 2022, The subject matter is the company’s shares held by Tacheng international, with a total of 64000000 shares, accounting for 7.0006% of the total share capital of the company. If the stock disposal auction is successful, it will not lead to changes in the controlling shareholder and actual controller of the company.

Beijing Konruns Pharmaceutical Co.Ltd(603590) it is planned to carry out the clinical trial of Agkistrodon acutus for injection

According to the announcement of Beijing Konruns Pharmaceutical Co.Ltd(603590) , the company has received the letter of opinions on the production of clinical test samples for the conversion of Agkistrodon acutus hemagglutinin for injection to pets issued by the Ministry of agriculture and rural areas. After the research of the Ministry of agriculture and rural areas, the company agrees in principle to use the current Agkistrodon acutus hemagglutinin preparation for injection to produce products produced in the workshop and carry out clinical trials to apply for veterinary drug registration. Agkistrodon acutus hemagglutinin for injection is intended to assist in hemostasis of superficial wound bleeding in dog surgery.

The company said that the research on the thrombin of Agkistrodon acutus for canine injection is a re research on the product after the listing of “suling”. After the successful listing of the product, it is expected to fill the market gap of the thrombin for canine injection, further expand the development of the incremental market of the thrombin, and bring a positive impact on the future performance growth of the company.

- Advertisment -